Shah Gaurav
CEO
Shah Gaurav has filed 9 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 9 of those filings fall inside the rolling window. Most recent filing: Aug 20, 2026.
On the most recent filing, Shah Gaurav is listed as CEO at ROCKET PHARMACEUTICALS, INC. Inside the rolling window, Shah Gaurav reported no open-market purchases and 8 open-market sales totaling $286K in RCKT. The largest disclosed transaction in the window is a sale of 55,684 RCKT shares on May 21, 2026, worth $172K.
Companies traded
Other insiders at RCKT
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$286K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Shah Gaurav made?
Shah Gaurav has filed 9 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Shah Gaurav trade?
Shah Gaurav has filed SEC Form 4 disclosures for 1 company, including RCKT.
When was Shah Gaurav's most recent SEC Form 4 filing?
Shah Gaurav's most recent SEC Form 4 filing on Tracefour is dated Aug 20, 2026.
What is Shah Gaurav's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Shah Gaurav is listed as CEO.
What is Shah Gaurav's total buy and sell value in the current window?
Inside the rolling retention window, Shah Gaurav bought $0 and sold $286K based on SEC Form 4 filings.
What was Shah Gaurav's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 55,684 RCKT shares on 2026-05-21, worth $172K, per SEC Form 4 filings.